Last reviewed · How we verify
Antivenom
Antivenom is a Small molecule drug developed by CTU. It is currently in Phase 2 development. Also known as: VINS Bioproduct.
Antivenom is a specific treatment for envenomation, composed of antibodies that is used to treat certain venomous bites and stings. It is given by injection and recommended only if there is significant toxicity or a high risk of toxicity, with the specific antivenom needed depending on the species involved.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Antivenom |
|---|---|
| Also known as | VINS Bioproduct |
| Sponsor | CTU |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Clinical Severity in Scorpion Envenomation: Home Remedies, Delay to Medical Care, and Antivenom Dosing Strategies in an Emergency Department
- Assessment of the Efficacy of Scorpion Antivenom Therapy in a Dose-response Manner, in Patients With Scorpionism (PHASE2, PHASE3)
- Evaluation of Anti-venoms Serum in Africa
- A Prospective Observational Study to Determine the Predictive Accuracy of Snakebite Severity Score (SSS) in Identifying Syndrome-Specific Core Outcome Parameters Amongst Envenomated Patients Presenting to the Emergency Department.
- Broad-spectrum Rapid Antidote: Varespladib Oral for Snakebite (PHASE2)
- Role of Steroids and Extended Scorpion Anti-Venom Use in Cardiac Affection Among Scorpion Stung Pediatric Cases (NA)
- Predictive Modeling of Necrotizing Skin Infections in Snakebite Patients
- Optimal Dose of Antivenom for Daboia Siamensis Envenomings (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antivenom CI brief — competitive landscape report
- Antivenom updates RSS · CI watch RSS
- CTU portfolio CI
Frequently asked questions about Antivenom
What is Antivenom?
Who makes Antivenom?
Is Antivenom also known as anything else?
What development phase is Antivenom in?
Related
- Manufacturer: CTU — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: VINS Bioproduct
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing